Edition:
India

Trillium Therapeutics Inc (TRIL.OQ)

TRIL.OQ on NASDAQ Stock Exchange Capital Market

6.65USD
22 Jun 2018
Change (% chg)

$-0.10 (-1.48%)
Prev Close
$6.75
Open
$6.80
Day's High
$6.80
Day's Low
$6.40
Volume
9,436
Avg. Vol
11,900
52-wk High
$13.30
52-wk Low
$4.10

Chart for

About

Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is... (more)

Overall

Beta: 1.58
Market Cap(Mil.): $70.92
Shares Outstanding(Mil.): 10.79
Dividend: --
Yield (%): --

Financials

BRIEF-Trillium Therapeutics Provides Update On Its Clinical Programs

* TRILLIUM THERAPEUTICS PROVIDES UPDATE ON ITS TTI-621 AND TTI-622 CLINICAL PROGRAMS

10 Apr 2018

BRIEF-Trillium Therapeutics' TTI-621 Receives Orphan Drug Designation For Treatment Of Cutaneous T-Cell Lymphoma

* TRILLIUM THERAPEUTICS' TTI-621 RECEIVES ORPHAN DRUG DESIGNATION FOR TREATMENT OF CUTANEOUS T-CELL LYMPHOMA Source text for Eikon: Further company coverage:

20 Mar 2018

BRIEF-Trillium Therapeutics Reports Annual 2017 Financial And Operating Results

* TRILLIUM THERAPEUTICS REPORTS ANNUAL 2017 FINANCIAL AND OPERATING RESULTS

09 Mar 2018

Earnings vs. Estimates